Short-term effect of an estroprogestin containing ethinyl-estradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism;Effetto a breve termine di un estroprogestinico contenente etinilestradiolo 20 mcg+drospirenone 3 mg in schema 24 + 4 a livello ormonale e cutaneo nell'iperandrogenismo ovarico

Minerva Ginecologica

Volumn 62, Issue 6, 2010, Pages 509-515

  Lello, S ^a   Pacifico, V ^a   Primavera, G ^a   Guardianelli, F ^a   Sorge, R ^b   Paoletti, A M ^c   Melis, G B ^c   Raskovic, D ^a   Colonna, L ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Acne vulgaris; Drospirenone; Estroprogestin; Hyperandrogenism

Indexed keywords

ANDROSTENEDIONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EPIANDROSTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ALDOSTERONE ANTAGONIST; ANDROSTANE DERIVATIVE; DROSPIRENONE; ESTROGEN; ESTROGEN PROGESTAGEN; ETHINYLESTRADIOL; PREGNANE DERIVATIVE;

ACNE; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ERYTHEMA; HUMAN; HYPERANDROGENISM; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEBORRHEA; SHORT COURSE THERAPY; SIDE EFFECT; SKIN EXAMINATION; SKIN HYDRATION; SKIN WATER LOSS; TREATMENT DURATION; ADOLESCENT; ADULT; DRUG COMBINATION; FEMALE; HOSPITALIZATION; ORAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPERANDROGENISM; NORPREGNENES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952219373     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30. (Pubitemid 11046650)
2. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-19. (Pubitemid 47195665)
3. Elsenbruch S, Hahn S, Kowalsky D, Öffner AH, Schedlowski M, Mann K et al. Quality of life, psychosocial wellbeing, and sexual satisfaction in women with polycistic ovary syndrome. J Clin Endocrinol Metab 2003;88:5801-7. (Pubitemid 38033054)
4. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005;153:853-60. (Pubitemid 43020236)
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
6. Schneider HP. Androgens and antiandrogens. Ann NY Acad Sci 2003;997:292-306. (Pubitemid 38491085)
7. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
8. Batukan C, Muderris H, Ozcelik B, Ozturk B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007;23:38-44.
9. Lello S, Primavera G, Colonna L, Vittori G, Guardianelli F, Sorge R et al. Effects of two estroprogestins containing ethynilestradiol 30 mg and drospirenone 3 mg and ethynilestradiol 30 mg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008;24:718-23.
10. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-56.
11. Maloney JM, Dietze P Jr, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. A randomized controlled trial. Obstet Gynecol 2008;112:773-81.
12. Pillsbury DM, Shelley WB, Kligman AM. A manual of cutaneous medicine. Philadelphia: Saunders; 1961.
13. Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997;36:416-8.
14. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35.
15. Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005;3:19-27. (Pubitemid 41608060)
16. Rissman R, Oudshoorn MHM, Hennik WE, Ponec M, Bouwstra JA. Skin barrier disruption by acetone: observation in a hairless mouse skin model. Arch Dermatol Res 2009;301:609-13.
17. Yamamoto A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res 1995;287:214-8.
18. Grosman N, Hvidberg E, Schou J. The effect of oestrogenic treatment on the acid mucopolysaccaride pattern in skin of mice. Acta Pharmacol Toxicol 1971;30:458-64.
19. Uzuka M, Nakajima K, Ohta S, Mori Y. The mechanism of estrogen-induced increase in hyaluronic acid biosynthesis, with special reference to estrogen receptor in the mouse skin. Biochim Biophys Acta 1980;627:199-206.
20. Pierard-Franchimond C, Letane C, Goffin V, Pierard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995;22: 151-4.